PAF-receptor antagonists WEB-2086 and WEB-2170 (WEBs) have been previously shown to induce differentiation in murine and human leukemia cells. The present study describes the apoptotic-differentiative effect of WEBs in all-trans-retinoic acid (ATRA)-sensitive (NB4) and -resistant (NB4-007-6 and NB4-MR4) acute promyelocytic leukemia (APL) cell lines as well as blasts from patients with t(15;17) APL. NB4 cells exposed to 0.5-1 mM WEBs underwent striking growth arrest and massive apoptosis without appreciable differentiation; IC 50 values after 3-day treatment of NB4 were 0.4 and 0.25 mM for WEB-2086 and WEB-2170, respectively. WEBs induced apoptosis also in the two ATRA-resistant NB4-007-6 and NB4-MR4 cell lines and in blasts from patients with t(15;17) APL. Moreover, subapoptotic WEBs acted synergistically with low-dose (0.025-0.05 lM) ATRA; this allowed to increase ATRA differentiation potential up to 40-fold and to improve both number and intensity of NBTpositive NB4 cells at definitely higher levels than with 1 lM ATRA alone. The powerful antiproliferative-apoptotic activities of WEBs in vitro on ATRA-sensitive, ATRA-resistant APL cells and blasts from patients with APL as well as drug capabilities to enhance ATRA differentiation potential suggested that these agents also due to their recognized tolerability in vivo might improve, alone or in combination, clinical treatment of APL.
Introduction
Differentiation therapy of acute promyelocytic leukemia (APL) by pharmacological doses of all-trans-retinoic acid (ATRA) has strikingly improved clinical outcome in a high percentage of APL cases. 1, 2 Nevertheless, both spontaneous and acquired resistance to ATRA 2, 3 still represent a problem for a number of APL patients requiring further treatments with either chemotherapy or alternative inducers. 4 Among these, arsenic trioxide (As 2 O 3 ) has been proven effective to treat both ATRA-sensitive and -resistant APL cells 3 by acting through ATRA-independent mechanisms 5 and promoting either apoptosis or partial differentiation of leukemia cells. 6 In addition, histone deacetylase inhibitors (HDACi) including n-butyrates, trichostatin A (TSA) and suberoylanilide hydroxamic acid (SAHA) [7] [8] [9] could restore ATRA-mediated transcriptional activity and induce differentiation of APL cells in vitro 10 and in animal models. 8 The aforementioned differentiation and 'transcription therapy' 11 of APL and, possibly, other hematologic malignancies 9, 12 has prompted the identification of new agents, which due to their low-toxicity and anticancer efficacy might have, prospectively, translational research opportunities.
Previous results from this laboratory showed that WEB-2086 and WEB-2170 (WEBs), known as powerful in vitro and in vivo antagonists of platelet-activating factor receptor (PAF-r), 13 could also induce differentiation in murine and human leukemia cell lines.
14 Here, we report that WEBs, as single agents, exerted a marked apoptotic effect in vitro on both ATRA-sensitive andresistant APL cell lines and on blasts from patients with t(15;17) APL. Moreover, it was found that suboptimal amounts of WEBs, which could not trigger apoptosis themselves, were, nevertheless, very effective in enhancing up to 40-fold ATRA differentiation potential in NB4 cells to bring benefits to pharmacological treatment of APL.
Materials and methods

Cell lines, culture condition and primary APL blasts
The ATRA-sensitive APL cell line NB4 15 and ATRA-resistant NB4 subclones NB4-007-6 16 and NB4-MR4 17 (gift of C Gambacorti-Passerini and WH Miller, respectively) were employed. Cells were maintained in RPMI 1640 (Bio-Whittaker Europe, Verviers, Belgium) supplemented with 10% fetal calf serum (FCS, EuroClone, Life Science Division, Milan, Italy) at 371C in a humidified atmosphere of 5% CO 2 . Cells were counted in a Bü rker chamber and cell viability was determined by the trypan blue exclusion test or WST-1 assay (Roche Applied Science, Indianapolis, IN, USA). 18 IC 50 value was the drug concentration needed to decrease cell mass by 50% as compared to control. Leukemic blasts from peripheral blood samples of three patients with APL (M3; FAB classification; 19 ) after giving informed consent were isolated by centrifugation at 1700 g on Lymphoprep (Eurobio, Les Ulis Cedex, France) and then cultured as above.
Reagents
PAF-r antagonists WEB-2086 and WEB-2170 13 (Boehringer Ingelheim Pharma KG, Biberach, Germany) were dissolved in dimethyl sulfoxide (DMSO, Sigma-Aldrich, St Louis, MO, USA) and stored at room temperature protected from light. The DMSO vehicle did not interfere with activities of WEBs. ATRA was from Sigma-Aldrich; all other chemicals employed were reagent grade.
Cell lysate preparation, SDS-PAGE and Western blot
Harvested cells were resuspended in lysis buffer (1% Triton X-100, 1 mM phenylmethylsulfonyl fluoride, 40 mM Tris-HCl pH 8.0, 150 mM NaCl) and sonicated (Microson XL-2000, Misonix, Farmingdale, NY, USA). Cell extracts were processed as described previously 20 using anticaspase-3, -8, -9 antibodies (Santa Cruz Biotech, Santa Cruz, CA, USA); the ECL procedure on Hyperfilm ECL (Amersham Biosciences, Buckinghamshire, UK) was employed for development.
Myeloid differentiation
Morphological changes in May-Grü nwald/Giemsa-stained cytosmears as well as expression of myeloid antigens CD11b and CD14 (FACScan cytofluorometer, Becton-Dickinson, San Jose, CA, USA) were evaluated. 14 For NBT reduction assay, cell suspensions (10 5 /ml complete medium) were incubated with NBT (0.25 mg/ml) and 12-O-tetradecanoyl-phorbol-13-acetate (500 ng/ml) (Sigma-Aldrich) for 30 min at 371C. NBT was evaluated both as % of positive cells and intensity of reduction at 570 nm (Cary 50 Scan spectrophotometer) (Varian, Victoria, Australia). 21 The values were reported as A 570 /0.5 Â 10 6 cells.
Determination of apoptosis
Apoptotic cells in the populations were measured with a FACScan flow cytometer (Becton-Dickinson) by the AnnexinVFluos Apoptosis detection kit (Roche Molecular Biochemicals, Mannheim, Germany). Usually, 1 Â 10 6 cells were used for labeling with Annexin-V-Fluos and propidium iodide (PI) in binding buffer according to the manufacturer's instructions. Cytosmears were stained as above and evaluated for nuclear condensation and the presence of apoptotic bodies. DNA fragmentation in cell (6 Â 10 6 ) extracts was assessed according to Blankenberg et al 22 and visualized on ethidium bromidestained 1.5% agarose gel.
Statistical analysis
All experiments were independently performed at least three times. All data were statistically analyzed by Student's t-test. Figure 1a ). Decrease in cell density was definitely more marked with WEBs than with 1 mM ATRA. The IC 50 values in 3-day treated cultures were approximately 0.4 and 0.25 mM for WEB-2086 and WEB-2170, respectively. However, morphologic examination of cell smears after a 3-day treatment (Figure 1b,  left) showed that, in contrast to ATRA, which prompted cells to differentiation, WEBs induced massive nuclear fragmentation suggestive of a typical apoptotic process. This was confirmed by DNA laddering in agarose gels (Figure 1b, right) and by cytofluorimetric analyses with Annexin V and PI double staining (Figure 1c) . Apoptotic markers occurred relatively early during treatment and involved 430% and 450% cells at day's 2 and 3, respectively. Negligible signs of WEB-induced NB4 maturation in terms of changes in cell morphology, NBT-positivity and CD11b or CD14 expression were detected up to day 5 of incubation (data not shown).
Results
WEB-2086-and WEB-2170-induced apoptosis in NB4 cells
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WEB-mediated activation of caspases
Caspase involvement in NB4 cells induced to apoptosis by WEBs was examined by Western blot showing that virtually identical protease activation patterns were obtained. Results of a typical experiment performed with 0.5 mM WEB-2170 ( Figure 2 ) indicated that in treated cells there was an early drug-induced processing of procaspase 9 and 8 to yield since day 1 cleaved products of approximately 37 and 20 kDa, respectively. The comparison between day 1 and 2 profiles suggested that also caspase 3 activation occurred as showed by the decrease in 33 kDa precursor protein and generation of 17 kDa active fragment.
Low-dose WEBs enhanced greatly the differentiation potential of ATRA Suboptimal concentrations of WEBs -such as 200 mM WEB-2086 or 100 mM WEB-2170 -given alone for 3 days caused only partial inhibition of cell growth (approximately 20-25% as compared to control) but did not trigger either apoptosis or functional differentiation as denoted by results of NBT reduction assay (Figure 3) . Comparable decreases in cell density were observed in cultures incubated with low amounts (0.025-0.050 mM) of ATRA which, on the other hand, also prompted differentiation of a minor portion of population to yield approximately 12-22% NBT-positive cells. However, the contemporary administration of low doses of ATRA and WEBs proved to be much more effective on NB4 differentiation than single agents alone. Cultures incubated for 3 days with 0.025 mM ATRA and 100 mM WEB-2170 or, alternatively, with 0.050 mM ATRA and 200 mM WEB-2086 showed marked increases in the number of NBT-positive cells up to levels 485%, which were significantly higher than in cultures treated with 1 mM ATRA alone. However, synergy between ATRA and WEBs was more accurately appreciated by the intensity at which NADPHoxidation process was induced. This was accomplished by measuring the amounts of accumulated formazan; it was found that NBT reduction activity at the cellular level was strongly enhanced by coadministration of low-dose ATRA þ WEBs to yield levels that were approximately two-fold higher than with 1 mM ATRA alone (Figure 3) . Consistently, percentages of CD11b positive cells in cultures treated with the two combinations of ATRA þ WEBs increased up to approximately 60%, that is, almost twice the values found in cultures treated with low-dose ATRA alone (Figure 3) . Eventually, morphologic evidences for potentiation of ATRA-induced maturation by WEBs were provided by examination of May-Grü nwald/Giemsa cytosmears. A 3-day incubation of NB4 cells with the two combinations of ATRA þ WEBs led to an increased proportion of cells, which appeared smaller in size and were characterized by less basophilic cytoplasm, lobed nuclei, and with a reduced nucleus-cytoplasm ratio (Figure 3 ). Synergistic induction of NB4 maturation by low-dose ATRA and WEBs was not paralleled by comparable effects on growth rates; cultures treated with the above drug combinations showed decreases in cell densities, which were virtually the sum of inhibitory effects by single agents.
WEBs induced apoptosis in ATRA-resistant APL cells
Effectiveness of WEBs on human promyelocytic cells was further evaluated by using two distinct ATRA-resistant APL cell lines, NB4-007-6 and NB4-MR4. Both cell lines responded promptly to WEBs by undergoing loss of viability and apoptosis as shown by nuclear condensation, cell shrinkage and formation of apoptotic bodies. Results concerning drug sensitivity, morphology and cytofluorymetric assay for Annexin V showed that, on the whole, the response of NB4-007-6 ( Figure 4a ) and NB4-MR4 cells (Figure 4b Western blot analysis of caspases in NB4-treated cultures. Cells were examined at day 1 and 2 of incubation without (control) and with 0.5 mM WEB-2170. Cell lysates (20 mg per lane) were separated on 12.5% SDS-PAGE gels. Caspase 9, 8 and 3 levels (percursors and cleaved proteins) were detected by means of primary monoclonal antibodies directed against specific protein and suitable secondary biotin-conjugated IgG preparations.
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A Laurenzana et al incubation with WEBs, and by day 3 approximately half of the ATRA-resistant population was committed to programmed cell death. A significant proportion of necrotic cells was also detected along with WEB-treatment of APL cell lines, and the NB4-007-6 cells exhibited the highest cell loss (66% when considering both apoptotic and necrotic cells) after a 2-day treatment. Importantly, exposure of ATRA-resistant APL cells to the aforementioned combinations of low-dose ATRA þ WEBs to verify their potential synergistic activities showed no appreciable induction of either differentiation or apoptosis.
WEB-2170 induced apoptosis in primary blasts (M3 subtype) from patients with APL
Primary blasts from distinct patients with t(15;17) APL responded to in vitro administration of WEBs by undergoing time-and dose-dependent changes in morphology and expression of apoptotic bodies. Most striking effects were seen after a 2-day incubation with 0.5 mM WEB-2170 ( Figure 5 ), and 450% apoptotic cells, over spontaneous apoptotic rates of controls, were counted.
Discussion
The present study demonstrated that WEB-2086 and WEB-2170, two hetrazepines originally developed as PAF-r antagonists, behave also as powerful antileukemic drugs in vitro. The main effect of WEBs used as single agents on APL cells was that of triggering apoptosis through the activaction of procaspase 8, 9 and 3, with no apparent differentiation. Drug-mediated apoptosis was dose dependent within a range of 0.25-1 mM WEBs in the ATRA-sensitive and -resistant APL cell lines (NB4, NB4-007-6 and NB4-MR4) and, noteworthy, also in primary blasts from distinct patients with t(15;17) APL whose leukemic cells in vitro were even more sensitive to WEBs than established APL cell lines. The substantial identity of response to WEBs by the three APL cell lines and primary APL blasts has suggested that WEBs did not share either mechanisms of action or molecular targets of ATRA. Instead, some analogies between WEBs and As 2 O 3 could, perhaps, be underscored as regards their (a) broad anticancer activities on a variety of malignant cells different from APL cells and (b) abilities to trigger apoptosis in vitro in both ATRA-sensitive and -resistant APL cells. 5, 6 Subapoptotic concentrations of WEBs, which only slightly inhibited cell growth as single agents, could synergize with low doses of ATRA and enhance up to 40-fold its differentiation potential in NB4 cells. Combinations of low dose 0.05 mM ATRA with 0.2 mM WEB-2086 or, alternatively, 0.025 mM ATRA with 0.1 mM WEB-2170 induced polymorphonuclear morphology, increased CD11b expression and NBT reduction activity as shown by both the number of cells recruited to functional maturation and, notably, the intensity of oxidative burst at single cell level. Overall, changes prompted by low-dose ATRA and WEBs were suggestive of granulocyte differentiation and, actually, even more advanced than those attained by treatment with 1 mM ATRA alone as suggested from preliminary data of microarray DNA technology (manuscript in preparation). Synergism between WEBs and ATRA might help in reducing both side-effects of ATRA 23 and upregulation of ATRA catabolism 24 and be significant to combination therapy of APL as reported for several HDACi; 8 the latter were also capable of enhancing ATRA-induced differentiation of NB4, but in contrast to WEBs, were inactive as sole agents.
Potentiation of ATRA-induced differentiation activity by WEBs was comparable to that reported with 1-2 mM HMBA 25 on ATRA-sensitive APL cells. This confirmed our previous observations on functional similarities between HMBA and WEBs exerting no HDACi activity 14 but also indicated that, on a molar 
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A Laurenzana et al basis, WEBs were definitely more effective inducers than HMBA. Moreover, it was worth mentioning that, unlike HMBA, the administration of WEBs to animal models and humans proved to be relatively safe up to a concentration of 400 mg/ day. 13, 26 The action mechanisms of WEBs in APL cells remain to be clarified. However, the involvement of classical PAF-mediated signal transduction pathways seemed to be ruled out by the fact that cytodifferentiation/apoptosis was triggered at WEB concentrations higher by far than those compatible with the highaffinity binding of drugs to PAF-r (K i r15 nM); 13 this suggested, therefore, that antileukemia activity of WEBs might pass through low-affinity PAF-r or even PAF-r-independent pathways. We are currently exploring the possibility that peripheral benzodiazepine receptors (PBR) might be involved in WEB-mediated apoptosis of APL cells. This hypothesis is supported by the facts that (a) WEBs -originally synthesized from benzodiazepineshave maintained the ability to bind PBR; 27 (b) specific PBRligands were reported to induce differentiation and/or apoptosis in a variety of malignant cells including human leukemia cell lines, 28 as well as to sensitize acute myeloid leukemia cells to cytotoxic agents and elicit apoptosis by altering mitochondrial membrane potential. 29 Overall, our findings showed that WEBs can be regarded as very attractive and multifaced molecules which, beyond exerting anti-inflammatory, 30 antineoangiogenetic 31 and antiproliferative and differentiative activities, 14 also have the ability of inducing in vitro apoptosis of both ATRA-sensitive andresistant APL established cell lines as well as primary blasts from patients with t(15;17) APL. Moreover, highly effective synergism In vitro effects of WEB-2170 on morphology (magnification: x650) of primary leukemic blasts from two t(15;17) APL cases (#1 and 2). Cells were incubated for 2 days without or with 0.5 mM drug and then examined as above for nuclear condensation and formation of apoptotic bodies.
A Laurenzana et al between WEBs and ATRA might help in decreasing by times ATRA concentrations at levels that might be less toxic, thus offering a new promise in the combined pharmacological treatment of APL.
